Daniel Pereira

Title: The Innovations of Daniel Pereira

Introduction

Daniel Pereira is an accomplished inventor based in Alexandria, VA (US). He has made significant contributions to the field of viral vector production, particularly through his innovative work on temperature-sensitive adeno-associated virus (AAV) proteins. His research has the potential to advance gene therapy techniques and improve the efficacy of viral vectors.

Latest Patents

Daniel Pereira holds a patent for "Temperature-sensitive regulation of viral vector production." This invention provides temperature-sensitive (ts) AAV Rep78 and Rep68 proteins. In preferred embodiments, the ts AAV Rep78 and Rep68 proteins have missense mutations at amino acid positions 40, 42, and 44 that confer a temperature-sensitive phenotype. The patent also includes nucleotide sequences and vectors encoding the inventive ts Rep proteins. Additionally, a hybrid adenovirus vector is provided that stably comprises a nucleotide sequence encoding a ts AAV Rep protein according to the invention. The present invention also outlines methods of packaging AAV vectors and methods of ex vivo gene delivery using the ts Rep proteins. Furthermore, it provides cells containing the ts AAV Rep proteins, preferably stably integrated into the genome of the cell.

Career Highlights

Daniel Pereira is affiliated with the University of North Carolina at Chapel Hill, where he continues to engage in groundbreaking research. His work has garnered attention for its innovative approach to viral vector production, which is crucial for advancing gene therapy applications.

Collaborations

Daniel has collaborated with notable researchers in his field, including Richard Jude Samulski and Nicholas Muzyczka. These collaborations have further enriched his research and contributed to the development of effective gene delivery systems.

Conclusion

Daniel Pereira's contributions to the field of viral vector production exemplify the importance of innovation in biotechnology. His patent on temperature-sensitive AAV proteins represents a significant advancement in gene therapy, showcasing his commitment to improving medical treatments.